Macrocyclic PD-1 Binders for Blocking PD-L1 Immune Evasion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The interaction between PD-1 and PD-L1 leads to immune evasion by cancer cells, resulting in decreased immune responses and T-cell exhaustion, which hampers effective immunotherapy for cancer treatment.
Innovation Solution
Development of macrocyclic compounds that inhibit the PD-1/PD-L1 protein interaction, thereby enhancing immune responses against cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PD-1 and PD-L1 interact, then cancer cells achieve immune evasion, but immune responses are decreased and T-cell exhaustion occurs
Solution Approach 1:
The patent introduces macrocyclic compounds as intermediary substances that bind to PD-1 and prevent its interaction with PD-L1. These compounds act as mediators that block the harmful interaction between cancer cell surface proteins, thereby reversing immune evasion and restoring effective immune responses without directly attacking the cancer cells themselves.
Solution Approach 2:
The patent extracts or separates the PD-1 protein from its interaction with PD-L1 by using macrocyclic compounds that specifically bind to PD-1. This extraction prevents the formation of the PD-1/PD-L1 complex, thereby eliminating the mechanism of immune evasion while preserving the ability of T cells to recognize and attack cancer antigens.
2Reliability
If PD-1/PD-L1 interaction is blocked, then immune suppression is reversed and T-cell function is restored, but new compound classes must be developed
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of macrocyclic compounds to optimize their binding affinity and specificity for PD-1. By adjusting parameters such as molecular size, functional groups, and spatial configuration, the compounds achieve enhanced efficacy in blocking PD-1/PD-L1 interaction while maintaining pharmacological safety profiles.
Solution Approach 2:
The patent employs composite material principles by integrating multiple functional moieties within the macrocyclic compound structure. These compounds combine protease inhibition capabilities with PD-1 binding activity, creating a multi-functional therapeutic agent that simultaneously addresses protein degradation and immune checkpoint blockade mechanisms.
Data Source
AI summary
In accordance with the present disclosure, macrocyclic compounds have been discovered that bind to PD-1 and are capable of inhibiting the interaction of PD-1 with PD-L1. These macrocyclic compounds exhibit in vitro immunomodulatory efficacy thus making them therapeutic candidates for the treatment of various diseases including cancer and infectious diseases.